Before the first lady came on board for the Clinton administration, many biotech analysts told their clients to sell all their biotechs, because the new administration wanted control over the pharma and biotech pricing. At the time, I worked with John Kapoor here in Chicago (we both have our PHDs from State U of New York at Buffalo around the same time/same school within the university).
The new secretary over the FDA should be someone with more experience with biotech and pharma.
By the way, today is the day for Dr. Khanna to present STAR study in Washington DC - Hedrick indicates he would try to post the poster on the CYTX website.
The following user(s) said Thank You: rodney.strongg